Biocept (BIOC) Stock Heads Up On Patent News

Biocept Inc (NASDAQ: BIOC) is trading in the green early on this morning, up more than 3% after announcing patent news. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

BIOC Stock Gains On Patent Award

In a press release issued early this morning, Biocept announced that it has been awarded a new patent. The South Korean patent No. 2010601 is titled “METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIANTS.”

In the release, BIOC said that the patent provides protection for its Switch-Blocker technology, the technology that is considered to be the core of its Target Selector assays. The Target Selector is designed for molecular analysis using real-time PCR, Sanger sequencing and next-generation sequencing.

In a statement, Lyle Arnold, Ph.D., CSO at BIOC, had the following to offer:

The issuance of this patent further expands Biocept’s intellectual property protection in Southeast Asia for rare mutation detection and adds to the portfolio of similar patents issued in the U.S., China, Australia, Japan, and Europe. The Switch-Blocker technology makes possible the ultra-sensitive detection of rare genetic events and is especially useful for detecting rare cancer associated mutations and alterations for use in Biocept’s liquid biopsy assays. This technology works seamlessly with Biocept’s other patented and proprietary technologies for blood collection, and CTC capture and analysis.

The above statement was followed up by Michael Nall, President and CEO at BIOC. Here’s what he had to offer:

Expanding U.S. and international patent protection for our Target Selector™ liquid biopsy platform is an important strategic focus as we seek to expand our global business through the sale of assays performed at Biocept and through Research Use Only (RUO) kits sold for use in a client’s own laboratory. With this newly granted patent, we now have 37 issued patents covering our tests and technologies and we plan to continue to invest in our intellectual property position by pursuing additional patent issuances in the future.

Why Investors Are Excited

At the end of the day, there are several reasons to be excited here. Below are what I believe to be the three most important reasons that this patent award is a big win:

Reason #1: The Warren Buffett Approach

Warren Buffett is one of the most successful investors who has ever lived. If you’ve ever taken time time to dig into his strategies and watch videos where he gives investment advice, you’ve probably heard something about an economic moat.

Buffett has always been clear that when he chooses a company to get involved with, he’s looking for a product that is protected from competition, creating a moat around the opportunity.

With every new patent awarded to BIOC, the company’s economic moat only grows stronger. At the end of the day, there’s quite a bit of value in patents surrounding liquid biopsies at the moment as the world continues to look for less invasive and more reliable diagnostic testing.

Continue Reading!

Click below to continue to the next reason that this news is so exciting.

Reason #2: Global Penetration

If you look at Biocept’s patent strategy, you’ll see that the company is not only focused on protecting its products here in the United States, but it has been building its intellectual property protection around the globe.

This is very important to note. After all, while the United States does offer the largest economic opportunity, the global marketplace opens the door to compelling growth.

Ultimately, if Biocept wasn’t interested in the global commercialization of its Target Selector, it wouldn’t be interested in building out its global IP protection. The bottom line here is that while the company is still small, BIOC is working to become a GLOBAL leader in liquid biopsies.

Reason #3: An Aggressive Approach

Finally, BIOC has been working aggressively to expand its global footprint. The news released today is just one step along a long road travelled with several steps ahead.

As the company continues to take an aggressive approach to tackle the global market, the value that the company provides to its investors will only grow!